Marion Provost

• A global pharmaceutical group in a case before the French Competition Authority and the Paris court of appeal relating to an alleged abuse of collective dominance concerning the “off label use” of its drug in the ophthalmic field.
• A global biopharmaceutical group in investigations led by the European Commission and the Swiss Competition Commission for potential involvement of a subsidiary in a worldwide cartel.
• A global animal health company in a complaint before the European Commission leading to the investigation of a potential “killer acquisition”.
• A major pharmaceutical firm on the lifecycle management of several drugs in one of their franchises, in the context of biosimilars’ entry on the market, with a focus on product hopping and commercial policies issues.
• A global support services company in the assessment of the opportunity to apply for leniency before the French Competition Authority (internal audit) and in the assessment of its compliance with certain rules of the French Commercial Code concerning price transparency and unfair commercial practices.
• A leading consumer packaged food and beverage company in a merger control filing before the European Commission.
• An international bank in the context of a major EU investigation concerning potential manipulation of the Euribor rate.
• A manufacturer of electronic devices in the context of an investigation by the French Competition Authority concerning a potential abuse of dominant position and anticompetitive agreements with its distributors.
• A sugar manufacturer during a dawn-raid conducted by the European Commission.
• Various clients regarding the conduct of internal audits.
• A wholesale distributor of automotive spare parts in a merger control filing before the European Commission.
• A wholesale distributor of automotive spare parts in a merger control filing before the French Competition Authority regarding the acquisition of sole control over a retailer of automotive spare parts for light vehicles.
• A manufacturer and distributor of frozen food in a merger control filing before the French Competition Authority regarding the acquisition of sole control over a competitor.
• A French insurance company on merger control issues arising from the acquisition of the French insurance and bank activities of a UK financial institution, which requires clearance by the French Competition Authority.

Includes matters handled at Dechert or prior to joining the firm.

• Actions en réparation des pratiques anticoncurrentielles/ Private Enforcement — Cour d’Appel de Paris (18 avril 2023)
• Sommet du Droit : Private enforcement, les entreprises face à l’effet ricochet — Conférence Décideurs (25 janvier 2023)
• Actions en réparation des pratiques anticoncurrentielles, State of private actions in the EU: the point of view of professionals — Conférence Concurrences, Paris (30 mars 2022)
  
• Life Sciences Academy, Enquêtes/Investigations — Paris, France (15 février 2022)
  
• EU Pharmaceutical Law Forum — Conférence virtuelle (17-20 mai 2021)
• Life Sciences Academy, Enquêtes/Investigations — Paris, France (15 février 2022)
• Transactions en droit de la concurrence — Business & Legal Forum, Paris France (12 octobre 2017)

• Pharmaceutical Antitrust Book — Concurrences (30 novembre 2023)
• Accords de report d'entrée : la sanction de 60,5 millions d'euros pour Teva et Cephalon confirmée — Blog de l’Usine Nouvelle (1^er novembre 2023)
• The Instrumentalization of Intellectual Property Rights for Anticompetitive Purposes in the Pharmaceutical Industry A New Territory for Competition Authorities in Europe — Concurrences (4 septembre 2023)
• France: Pedagogical approach of courts and increased FCA enforcement contribute to rise in private antitrust litigation — Global Competition Review (30 juillet 2023)
• Impactful decisions exemplify FCA and Supreme Administrative Court's evolving merger control — Global Competition Review (30 juin 2023)
• Vers un élargissement du champ du contrôle des autorités de concurrence européennes dans les concentrations d’entreprises — Blog de l’Usine Nouvelle (14 avril 2023)
• Dominance in the pharmaceutical sector: An Overview of EU and national case law — Concurrences (2 mars 2023)
• Pourquoi la Commission européenne a interdit l'opération Illumina/Grail — Blog de l’Usine Nouvelle (21 octobre 2022)
• Le secteur de la santé sous la présidence d'Emmanuel Macron : rétrospectives et perspectives — Concurrences (31 mars 2022)
• Affaire Plavix : revirement dans le volet « private enforcement » — Blog L’Usine Nouvelle (26 mars 2022)
• Principe d’effectivité, notion d’unité économique et responsabilité civile : de quelques enseignements de l’affaire Sumal — Revue Concurrences (24 février 2022)
  
• Global Competition Review Cases and Precedents: Vertical Restraints – Global Competition Review (3 janvier 2022)
• Cartel Regulation — Getting The Deal Through (3 janvier 2022)
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — e-Competitions Review (Décembre 2021)
• Sanction de Roche et Novartis pour discours « trompeur » sur l’utilisation d’Avastin dans la DMLA : quand l’Autorité de la concurrence s’érige en censeur des communications entre les laboratoires et les autorités de santé — Blog Usine Nouvelle (25 janvier 2021)
• Covid-19, coopération entre entreprises et concurrence : quelles règles face à la crise ? — L'Usine Nouvelle (12 mai 2020)
• Indemnisation des préjudices résultant de pratiques anticoncurrentielles : le « pass-on » est-il le maillon faible ? — Actualités du droit (22 janvier 2020)
• Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law — e-Competitions Review (November 21, 2019)
• La transaction devant l'Autorité de la concurrence : au-delà des apparences, les entreprises ont- elles vraiment à y gagner ? — Revue Lamy Droit des Affaires (24 mai 2019)